Novartis leads and Bristol lags on novel drug approvals
Big pharma delivered 76 novel medicines to the market over the past five years, but some companies contributed more than others.
Sigilon hold hurts ahead of key haemophilia meeting
After a patient develops inhibitors questions emerge about a new approach to treating haemophilia A.
Oncopeptides gives with one hand and takes away with the other
Upon review Pepaxto beats Pomalyst on progression-free survival, but new overall survival data trigger clinical hold and threaten the programme.
Why Glaxo should buy Biohaven
And four other potential targets that could make sense for the beleaguered group.
Big pharma leads the way in stock market resurgence
And Lilly was well ahead of the pack, fuelled by Alzheimer’s hopes.
Biopharma takeovers dry up
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
Smaller companies set for third-quarter catalysts
The third quarter will see important data for Travere, Radius and Sio Gene, among other small developers.
